Tirzepatide (Mounjaro): Why Weight Loss Results Exceed Expectations

When someone first hears about weight loss injections, the first question is usually: isn't this just another fad? Tirzepatide — the active ingredient in Mounjaro — answered this question back in 2022. Over 75,000 clinical trial participants, FDA approval first for diabetes, then for weight management. And most importantly — results that exceeded even semaglutide.

What do those who've already tried it say? DOZA clients share their experiences — and the numbers speak for themselves.

What is tirzepatide and why it's not just another injection

Tirzepatide is a synthetic 39-amino acid polypeptide developed by Eli Lilly. In May 2022, the FDA approved it under the name Mounjaro for treating type 2 diabetes [2]. In November 2023, the same tirzepatide received separate approval for weight management under the name Zepbound [2].

This is not an Ozempic analog. It's a separate molecule with a unique mechanism.

Semaglutide, the active ingredient in Ozempic, came first — and was long considered the gold standard. But tirzepatide works differently. It activates two receptors instead of one [3]. And this explains the difference in results.

The molecular modification is also interesting. The fatty acid side chain was changed from C18 diacid (as in semaglutide) to C20 diacid [3]. This provides long-lasting action — one injection per week. No daily pills, no constant reminders.

If you're hearing about this molecule for the first time and want to understand how it works — read the detailed material about Mounjaro (tirzepatide) on our website.

The key difference from other weight loss approaches: tirzepatide doesn't "burn fat" directly and isn't a stimulant. It restores the natural appetite regulation mechanism, which is disrupted in most people with excess weight. After a few weeks on tirzepatide, clients describe not "willpower" and "restraint" — but simply the absence of former interest in food.

Another important fact: tirzepatide is not addictive and doesn't affect the dopamine system. It's not a stimulant, not amphetamine, not a "magic wand." It's a molecule that reproduces and enhances natural hormonal signals that should be responsible for satiety after eating.

Dual GLP-1 + GIP mechanism: why it's more important than it seems

To understand why tirzepatide is more effective, you need to understand the hormones.

GLP-1 is the satiety hormone. It slows gastric emptying and sends a signal to the brain: there's enough food. Semaglutide works through this mechanism. People eat less because they feel full sooner.

But tirzepatide goes further. It also activates the GIP receptor [1].

GIP plays a special role. It enhances GLP-1 action and simultaneously affects fat tissue directly [4]. This improves fat distribution in the body and reduces fat accumulation where it doesn't belong — in the liver, muscles, around organs [4].

Studies showed: tirzepatide has higher affinity for the GIP receptor and demonstrates comparable activity to native GIP [1]. For the GLP-1 receptor — activity is slightly lower than natural GLP-1, but this is compensated by the dual mechanism [1].

What does this mean practically? Even the minimum tirzepatide dose of 5 mg (15% weight loss) exceeds the maximum semaglutide dose of 2.4 mg (14.9%). For many, this becomes the deciding argument.

The SURMOUNT-5 study confirmed a direct comparison: participants on tirzepatide lost an average of 23 kg, on semaglutide — 15 kg [2]. More details about comparison of tirzepatide and semaglutide.

The practical difference clients talk about: on semaglutide appetite decreases, but food thoughts remain. You want it, but eat less. On tirzepatide — most describe "silence": food becomes just food, not a constant background issue. This explains higher effectiveness with the same protocol adherence.

There's another advantage of the dual mechanism: impact on insulin resistance. The GIP receptor is involved in insulin sensitivity regulation. Therefore, DOZA clients with prediabetes or elevated sugar often notice improved test results within 4–8 weeks of the program — not just weight loss, but overall metabolic improvement.

SURMOUNT-1: what the largest tirzepatide study showed

In 2022, Eli Lilly published results of SURMOUNT-1 — a randomized controlled study with 2,539 adults with obesity or overweight. 72 weeks, three tirzepatide doses: 5 mg, 10 mg, and 15 mg. This isn't a small study — it's one of the largest clinical trials in the weight management category in modern history.

Results shattered previous ideas about medical weight loss limits. On 5 mg dose, participants lost an average of 15.0% of initial body weight. On 10 mg dose — 19.5%. On maximum 15 mg dose — 20.9%. For someone with starting weight of 100 kg, that's minus 15, 20, or 21 kg respectively.

For comparison: the STEP-1 study (semaglutide 2.4 mg, 68 weeks) showed average weight loss of 14.9%. So even the minimum therapeutic tirzepatide dose of 5 mg exceeds the maximum approved semaglutide dose. Direct comparison SURMOUNT-5 confirmed: tirzepatide participants lost an average of 23 kg versus 15 kg on semaglutide.

Another important fact from SURMOUNT-1: 89% of participants on 15 mg dose achieved more than 5% weight loss, 82% — more than 10%, 56% — more than 20%. So more than half of participants on maximum dose lost a fifth of their weight. This had never been seen in clinical studies before.

But what's more important for practice: even on 5 mg dose, which is the first stable dose after starting, 67% of participants achieved more than 10% weight loss. So even if your body doesn't "allow" dose increases — the result will still be significant.

Another quality indicator: in SURMOUNT-1, over 63% of participants on all three doses completed 72 weeks of study. For comparison — in most dietary studies, protocol completion rates are much lower. This means tirzepatide is tolerated well enough for people to continue — and get results.

DOZA client reviews: 4 stories with real numbers

Clinical studies are statistics. But what does a specific person experience? Here are several stories from our clients.

Story 1: First month, 34 years old

Starting weight: 89 kg. Dose: 2.5 mg (starting). Result after 4 weeks: -5.2 kg.

"I expected side effects I read about online. Had mild nausea for the first three days, then it passed. But what's strange — I simply forgot about snacking. Wasn't restraining myself, just really didn't want to."

Story 2: Three months, 47 years old, male

Starting weight: 112 kg. Current dose: 7.5 mg. Result: -14.8 kg, which is 13.2% of initial weight.

"My wife noticed first. I initially didn't believe it would work — tried so many things. Now I tighten my belt three holes tighter. And more energy, even though I eat less."

Story 3: Six months, 52 years old

Starting weight: 98 kg. Current dose: 10 mg. Result: -19.6 kg, or 20% of initial weight.

"Continued after three months because I realized — this isn't a diet you have to endure. It's just a different way of eating. I can easily refuse dessert because I don't want it. Previously this was impossible."

Story 4: Quick start, 28 years old

Starting weight: 76 kg (BMI 28). Dose: 5 mg. Result after 8 weeks: -8.4 kg (11%).

"I didn't need to lose 30 kg. But these 8 kilograms — they never came off with diets. Always returned. Now I've been maintaining 67–68 kg for three weeks."

What's included in the DOZA program:

• Initial specialist consultation
• Dosage selection for your goals
• Original product with delivery
• Support throughout the program
• Exit recommendations to maintain results

About how to choose the starting dose — in the article Mounjaro dosing. If you have questions about insulin resistance — Mounjaro for insulin resistance.

First step — free consultation. A DOZA specialist will assess your situation, answer questions and help understand if tirzepatide is right for you. No pressure, no obligations.

The next step is yours: go to Mounjaro catalog or book a consultation.

What unites all these cases? No client starved or went on a strict diet. Two of four didn't even exercise systematically. The only thing that changed — weekly injection and DOZA specialist support. Appetite decreased naturally, portions reduced naturally, habits transformed gradually — without stress and willful self-coercion.

Important detail: all four had different starting situations — different age, weight, gender, lifestyle. But tirzepatide worked in every case. The difference — only in pace and dose. This well illustrates one of the key advantages of the DOZA protocol: the program adapts to you, not vice versa.

Tirzepatide vs semaglutide — the main difference in numbers

The most common question from DOZA clients: "I tried Ozempic — how is Mounjaro better?" The answer isn't in marketing, but in mechanism and numbers.

Semaglutide is a GLP-1 agonist. It reduces appetite, slows gastric emptying, improves sugar regulation. This is already much better than any diet without support. But tirzepatide adds the GIP receptor — a hormone that enhances satiety signal and separately affects fat tissue. Dual action = deeper appetite control and better metabolic profile.

What does this mean practically? DOZA clients on tirzepatide more often describe the effect as "stopped thinking about food at all" — rather than just "eating less." This is a qualitative difference in experience that affects program adherence and long-term results.

Detailed comparative analysis with tables for each parameter — on the page Mounjaro vs Ozempic.

Important to understand: semaglutide and tirzepatide aren't competitors in terms of safety. Both are verified, both effective. The difference is in degree of effectiveness and mechanism. For most DOZA clients setting a goal of minus 15+ kg, tirzepatide gives much more predictable results.

If you've already tried semaglutide and weren't satisfied with results — switching to tirzepatide is a reasonable next step. The dual mechanism often gives better response precisely in those for whom GLP-1 alone proved insufficient. A DOZA specialist will help assess your situation and select starting dose.

Practical summary: tirzepatide today is the most clinically confirmed option for medical weight management. Not because it's "new," but because real data stands behind it — and real cases like the four clients you just read about.

In SURMOUNT-1, the best results were achieved by the group that reached therapeutic doses. Reproduce these doses directly through DOZA: Mounjaro 5 mg (minimum dose with -15% weight), Mounjaro 10 mg (-19.5%) and Mounjaro 15 mg (-20.9%) — all original Eli Lilly KwikPen, thermal box 2–8 °C, 1–2 days delivery. DOZA helps choose the starting dose for your BMI and goal.

Common questions about tirzepatide

Where to order DOZA products

DOZA supplies all products mentioned in the article with official cold chain and 24/7 specialist support. Choose what you need:

• Buy Ozempic in Ukraine — original semaglutide from Novo Nordisk with thermal delivery. Current Ozempic prices 2026 — from 1,600 ₴ for starting dose.

Where to buy

DOZA supplies the products mentioned in this article with an official cold chain and 24/7 specialist support:

• Buy Mounjaro in Ukraine — DOZA catalog with all 6 doses (2.5–15 mg) and official 24h cold-chain delivery. Current Mounjaro prices.